Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD 99.60
-1.30 (-1.29%)
Sep 10, 2025, 4:08 PM HKT
Innovent Biologics Employees
Innovent Biologics had 5,659 employees as of December 31, 2024. The number of employees increased by 787 or 16.15% compared to the previous year.
Employees
5,659
Change (1Y)
787
Growth (1Y)
16.15%
Revenue / Employee
2.02M HKD
Profits / Employee
200.45K HKD
Market Cap
170.59B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5,659 | 787 | 16.15% |
| Dec 31, 2023 | 4,872 | -422 | -7.97% |
| Dec 31, 2022 | 5,294 | -274 | -4.92% |
| Dec 31, 2021 | 5,568 | 2,289 | 69.81% |
| Dec 31, 2020 | 3,279 | 1,297 | 65.44% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 11,000 |
| Hansoh Pharmaceutical Group Company | 8,989 |
| JD Health International | 3,564 |
| Sino Biopharmaceutical | 24,379 |
| WuXi Biologics | 12,575 |
| Akeso | 3,035 |
| CSPC Pharmaceutical Group | 21,400 |
| Sichuan Kelun-Biotech Biopharmaceutical | 1,837 |
Innovent Biologics News
- 11 hours ago - Fangzhou and Innovent Biologics Form Strategic Alliance for AI-Powered Weight Management Solutions - GlobeNewsWire
- 2 days ago - Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were ... - GuruFocus
- 2 days ago - Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress - PRNewsWire
- 14 days ago - Innovent Biologics estimates ~50% jump in 2025 revenue - Seeking Alpha
- 14 days ago - Innovent Biologics reports interim results - Seeking Alpha
- 14 days ago - Innovent Announces 2025 Interim Results and Business Updates - PRNewsWire
- 16 days ago - Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study ... - GuruFocus
- 16 days ago - Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer - PRNewsWire